CML-164 Dihydroorotate Dehydrogenase Inhibition Reveals Metabolic Vulnerability in Chronic Myeloid Leukemia
Mulas, Olga;Caocci, Giovanni;
2022-01-01
Abstract
There are chronic myeloid leukemia (CML) patients who show resistance to TKI therapy and are prone to progress to more advanced phases of the disease, and new therapeutic approaches are needed. Our study shows that CML cells are vulnerable to dihydroorotate dehydrogenase (DHODH) inhibition mediated by Meds433, a potent DHODH inhibitor developed by our group.File | Size | Format | |
---|---|---|---|
1-s2.0-S2152265022013660-main.pdf open access
Size 127.85 kB
Format Adobe PDF
|
127.85 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.